SAT0408 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase 3, Randomized, Controlled Trials
Philip J. Mease(Providence College), C. Birbara(University of Massachusetts Chan Medical School), Randall M. Stevens, Maurizio Cutolo(Ospedale Policlinico San Martino), Dafna D. Gladman(Toronto Western Hospital), K. Shah, Juan J. Gómez‐Reino(Hospital Clínico Universitario de Valencia), Georg Schett(Karolinska University Hospital), C. Hu, Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Arthur Kavanaugh(University of California System), Ade Adebajo(University of Sheffield), J. Wollenhaupt(Schön Klinik Hamburg Eilbek), Éric Lespessailles(Université d'Orléans)
Cited by 17
Related Papers
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
|The Lancet|2000|1.5k